

## Correction: Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8<sup>+</sup> T cells

To cite: Jiang D, Huang A, Zhu B-X, *et al.* Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8<sup>+</sup>T cells. *Journal for ImmunoTherapy of Cancer* 2024;12:e010148. doi:10.1136/jitc-2024-010148.

In this article, affiliations 1 and 2 have been updated from (1) Sun Yat-sen University School of Life Science, Guangzhou, Guangdong, China; (2) Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China to (1) Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, China; (2) State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*J Immunother Cancer* 2024;12:e010148. doi:10.1136/jitc-2024-010148corr1

